Transgene Biotek Ltd

BSE: 526139

total announcements

TRABI.BO · 15 min delayed

Key Stats · Yahoo Finance · as of 20 Oct 2026

Market Cap

₹19 Cr

EPS (TTM)

₹-0.21

52W Low

₹1.83

52W High

₹4.35

Dividend Yield

0.00%

Beta

0.97

Price / Book

2.3

Debt / Equity

204.6

Revenue (TTM)

₹22,17,000.00

Gross Margin

99.91%

Operating Margin

-165.83%

Announcements Discussion

BSEBoard MeetingAuditor Change10 Oct 2026

Transgene Biotek Ltd

Appointment of Statutory Auditors to fill the Casual Vacancy The Board of Directors, based on the recommendation of the Audit Committee, has approved the appointment of M/s. Eswara Rao & Co., Chartered Accountants (Firm Registration No. 000816S), represented by Ms. Karra Pranavi, Partner (Membership No. 232994), as the Statutory Auditors of the Company to fill the casual vacancy arising due to the resignation of M/s. Vasavi & Co., Chartered Accountants, ....

Transgene Biotek Ltd has appointed M/s. Eswara Rao & Co. as its new Statutory Auditors to fill the casual vacancy arising from the resignation of M/s. Vasavi & Co. The appointment is subject to the approval of the company's members at a general meeting.

Read more →📎 1 attachment

BSECompany Update3 Oct 2026

Transgene Biotek Ltd

Statement of Deviation & Variation, 30-09-2026.

Transgene Biotek Ltd has submitted a statement stating that the Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable for the quarter ended 30th September 2026 as there was no public issue, rights issue, preferential issue, etc. during the quarter.

Read more →📎 1 attachment

BSEGeneralRegulatory3 Oct 2026

Transgene Biotek Ltd

Compliance -57(5) Intimation after the end of quarter

Transgene Biotek Ltd has informed BSE that Regulation 57(5) of SEBI (LODR) Regulations, 2015 is not applicable to the company for the quarter ended September 30, 2026, as no non-convertible securities were issued.

Read more →📎 1 attachment

BSEGeneralRegulatory3 Oct 2026

Transgene Biotek Ltd

Compliance -57(4)

Transgene Biotek Ltd has informed BSE that Regulation 57 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 is not applicable to the company as there are no non-convertible securities for which interest/dividend/principal is payable during the quarter.

Read more →📎 1 attachment

BSEGeneralRegulatory3 Oct 2026

Transgene Biotek Ltd

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December, as applicable ....

Transgene Biotek Ltd has confirmed that it does not fall under the category of 'Large Corporate' as per SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and BSE Circular No. LIST/COM/05/2019-20 dated April 11, 2019.

Read more →📎 1 attachment

BSECompany Update3 Oct 2026

Transgene Biotek Ltd

Compliance Certificate 7(3) as on 30-09-2026.

Transgene Biotek Ltd has submitted a compliance certificate to the BSE, confirming that its Registrar and Share Transfer Agent, Bigshare Services Private Limited, maintains all activities related to physical and electronic share transfer facilities.

Read more →📎 1 attachment

BSECompany Update3 Oct 2026

Transgene Biotek Ltd

Compliances Certificate under Reg. 74(5)

Transgene Biotek Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018, confirming the dematerialization and rematerialization of shares through NSDL & CDSL from July 1 to September 30, 2026.

Read more →📎 1 attachment

BSEBoard MeetingAuditor Change2 Oct 2026

Transgene Biotek Ltd